Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies

Sandra Davern, Lian X. Tang, Teresa K. Williams, Sallie D. Macy, Jonathan Wall, Deborah T. Weiss, Alan Solomon

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Overproduction of plasma cell-derived monoclonal free κ or λ immunoglobulin light chains (FLCs) is a hallmark of multiple myeloma, AL amyloidosis, and light chain deposition disease. Because these components serve as unique cellular and serologic biomarkers, their detection and quantitation has diagnostic, therapeutic, and prognostic import. In this regard, we have developed monoclonal antibodies (mAbs) that specifically recognize the κ or λ FLC products of all known human variable and constant region light chain genes. We now report the results of our studies that have demonstrated the capability of these reagents to measure, in a modified fluid-phase capture enzyme-linked immunosorbent assay (ELISA), serum κ and λ FLCs at concentrations as low as 5 and 15 ng/mL, respectively. The mAb-based ELISA has greater sensitivity and reproducibility than does the commercially available immunoturbidimetric assay that uses polyclonal anti-FLC antibodies. In addition, the mAbs can immunostain monoclonal FLC-producing plasma cells and pathologic light chain-related amyloid and nonfibrillar tissue deposits. Our anti-FLC mAbs, with their high degree of reactivity and versatility, may provide an invaluable tool in the diagnosis and management of light chain-associated disease.

Original languageEnglish (US)
Pages (from-to)702-711
Number of pages10
JournalAmerican Journal of Clinical Pathology
Volume130
Issue number5
DOIs
StatePublished - Nov 1 2008

Fingerprint

Immunoglobulin Light Chains
Monoclonal Antibodies
Light
Plasma Cells
Enzyme-Linked Immunosorbent Assay
Amyloidosis
Multiple Myeloma
Amyloid
Biomarkers
Antibodies
Serum
Genes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. / Davern, Sandra; Tang, Lian X.; Williams, Teresa K.; Macy, Sallie D.; Wall, Jonathan; Weiss, Deborah T.; Solomon, Alan.

In: American Journal of Clinical Pathology, Vol. 130, No. 5, 01.11.2008, p. 702-711.

Research output: Contribution to journalArticle

Davern, Sandra ; Tang, Lian X. ; Williams, Teresa K. ; Macy, Sallie D. ; Wall, Jonathan ; Weiss, Deborah T. ; Solomon, Alan. / Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. In: American Journal of Clinical Pathology. 2008 ; Vol. 130, No. 5. pp. 702-711.
@article{40f2d9b806894b398e3d212a8d579b8a,
title = "Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies",
abstract = "Overproduction of plasma cell-derived monoclonal free κ or λ immunoglobulin light chains (FLCs) is a hallmark of multiple myeloma, AL amyloidosis, and light chain deposition disease. Because these components serve as unique cellular and serologic biomarkers, their detection and quantitation has diagnostic, therapeutic, and prognostic import. In this regard, we have developed monoclonal antibodies (mAbs) that specifically recognize the κ or λ FLC products of all known human variable and constant region light chain genes. We now report the results of our studies that have demonstrated the capability of these reagents to measure, in a modified fluid-phase capture enzyme-linked immunosorbent assay (ELISA), serum κ and λ FLCs at concentrations as low as 5 and 15 ng/mL, respectively. The mAb-based ELISA has greater sensitivity and reproducibility than does the commercially available immunoturbidimetric assay that uses polyclonal anti-FLC antibodies. In addition, the mAbs can immunostain monoclonal FLC-producing plasma cells and pathologic light chain-related amyloid and nonfibrillar tissue deposits. Our anti-FLC mAbs, with their high degree of reactivity and versatility, may provide an invaluable tool in the diagnosis and management of light chain-associated disease.",
author = "Sandra Davern and Tang, {Lian X.} and Williams, {Teresa K.} and Macy, {Sallie D.} and Jonathan Wall and Weiss, {Deborah T.} and Alan Solomon",
year = "2008",
month = "11",
day = "1",
doi = "10.1309/AJCPNS6K1CYJPDBA",
language = "English (US)",
volume = "130",
pages = "702--711",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies

AU - Davern, Sandra

AU - Tang, Lian X.

AU - Williams, Teresa K.

AU - Macy, Sallie D.

AU - Wall, Jonathan

AU - Weiss, Deborah T.

AU - Solomon, Alan

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Overproduction of plasma cell-derived monoclonal free κ or λ immunoglobulin light chains (FLCs) is a hallmark of multiple myeloma, AL amyloidosis, and light chain deposition disease. Because these components serve as unique cellular and serologic biomarkers, their detection and quantitation has diagnostic, therapeutic, and prognostic import. In this regard, we have developed monoclonal antibodies (mAbs) that specifically recognize the κ or λ FLC products of all known human variable and constant region light chain genes. We now report the results of our studies that have demonstrated the capability of these reagents to measure, in a modified fluid-phase capture enzyme-linked immunosorbent assay (ELISA), serum κ and λ FLCs at concentrations as low as 5 and 15 ng/mL, respectively. The mAb-based ELISA has greater sensitivity and reproducibility than does the commercially available immunoturbidimetric assay that uses polyclonal anti-FLC antibodies. In addition, the mAbs can immunostain monoclonal FLC-producing plasma cells and pathologic light chain-related amyloid and nonfibrillar tissue deposits. Our anti-FLC mAbs, with their high degree of reactivity and versatility, may provide an invaluable tool in the diagnosis and management of light chain-associated disease.

AB - Overproduction of plasma cell-derived monoclonal free κ or λ immunoglobulin light chains (FLCs) is a hallmark of multiple myeloma, AL amyloidosis, and light chain deposition disease. Because these components serve as unique cellular and serologic biomarkers, their detection and quantitation has diagnostic, therapeutic, and prognostic import. In this regard, we have developed monoclonal antibodies (mAbs) that specifically recognize the κ or λ FLC products of all known human variable and constant region light chain genes. We now report the results of our studies that have demonstrated the capability of these reagents to measure, in a modified fluid-phase capture enzyme-linked immunosorbent assay (ELISA), serum κ and λ FLCs at concentrations as low as 5 and 15 ng/mL, respectively. The mAb-based ELISA has greater sensitivity and reproducibility than does the commercially available immunoturbidimetric assay that uses polyclonal anti-FLC antibodies. In addition, the mAbs can immunostain monoclonal FLC-producing plasma cells and pathologic light chain-related amyloid and nonfibrillar tissue deposits. Our anti-FLC mAbs, with their high degree of reactivity and versatility, may provide an invaluable tool in the diagnosis and management of light chain-associated disease.

UR - http://www.scopus.com/inward/record.url?scp=55249100513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249100513&partnerID=8YFLogxK

U2 - 10.1309/AJCPNS6K1CYJPDBA

DO - 10.1309/AJCPNS6K1CYJPDBA

M3 - Article

C2 - 18854262

AN - SCOPUS:55249100513

VL - 130

SP - 702

EP - 711

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -